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MECHANISM BY WHICH INSULIN AND ITS MIMETICS, SELENATE
AND VANADATE, REGULATE GLUCOSE-6-PHOSPHATE
DEHYDROGENASE GENE EXPRESSION
Sanjay M. Jivraj, M.S.
Western Michigan University, 1998
Glucose-6-phosphate dehydrogenase (G6PDH) is a key enzyme of the pentose
phosphate pathway. It controls the carbon flow through this pathway, producing
reducing equivalents in the form of NADPH to meet the cellular need for reductive
biosynthesis and the maintenance of the cellular redox state. Hepatic expression of
G6PDH has been shown to be regulated by hormones, nutrients and some growth
factors, however the mechanism by which these factors regulate G6PDH gene
expression has not been characterized. Here we investigate the mechanism by which
insulin and its mimetics, selenate and vanadate, regulate G6PDH gene expression.
Insulin exerts its tissue specific affect by binding to the cell surface receptor
initiating a phosphorylation cascade that reaches a variety of cytosolic and nuclear
targets. Using well characterized inhibitors of the insulin signal transduction pathway
we demonstrate that PI 3-K and S6K are essential for insulin to regulate G6PDH gene
expression, where as the proteins of the Ras/Raf/MAPK pathway are not required.
Furthermore, we show that the mimetics, selenate and vanadate, utilize different
proteins of the insulin signaling cascade to regulate G6PDH gene expression.
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CHAPTER I
INTRODUCTION
Insulin
Insulin is the most potent physiological anabolic agent known that is released
into the bloodstream by the P-cells of the pancreatic islets in response to high blood
sugar levels. It regulates diverse physiological processes in a wide variety of cells and
tissues (Figure 1), however in muscle, liver, and adipose tissues it primarily
stimulates the synthesis and storage of carbohydrates, lipids, and proteins while
inhibiting their degradation and release into circulation.

Amino Acid Uptake (All cells) (+)
Glucose Uptake (Muscle and adipocytes) {+)
Fatty Acid Synthesis (Adipocytes and liver) {+)
Gene Expression (All cells) (+/-)
Glycogen Synthesis (Muscle and Liver) (+)
Protein Synthesis (All cells) (+)
Glycolysis (Liver) (+)
Gluconeogenesis (Liver) (-)
DNA Synthesis (All Cells) (+)
Apoptosis (All Cells) (-)

Figure 1. Physiological Processes Regulated by Insulin Upon Binding to Its Cell
Surface Receptor. (+) = Processes Stimulated by Insulin, and (-) =
Processes Inhibited by Insulin.
1
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The physiological importance of insulin is revealed in diabetes mellitus, a
disease that affects 5% of the population in the United States. Diabetes mellitus is
classified into two basic types: Insulin-dependent diabetes mellitus (IDDM) and non
insulin-dependent diabetes mellitus (NIDDM), both characterized by high levels of
circulating glucose (Table 1).
Table 1
Comparison of Insulin Dependent Diabetes Mellitus (IDDM) and Non
Insulin Dependent Diabetes Mellitus (NIDDM)
Characteristic

IDDM

NIDDM

Level of insulin secretion

None or almost none

Normal or may exceed
normal

Typical age of onset

Childhood

Adulthood

Percentage of diabetics

10-20%

80-90%

Basic defect

Destruction of pancreatic
13 cells

Reduced sensitivity of
insulin's target cells

Associated with obesity

No

Usually

Genetic and
environmental factors
participating in disease?

Yes

Yes

Speed of development of
symptoms

Fast

Slow

3
The mechanism by which insulin exerts its cell and tissue specific effect has
only begun to be recently unraveled, as many investigators focus on the role of
protein phosphorylation in insulin action. This has led to the identification of a
complex network of interrelated and independent signaling pathways engaged in the
cell by insulin.
Mechanism of Insulin Action
Following the release by the P-cells of the pancreas, insulin binds to its
receptors on the surface of most cells.

Classic insulin-responsive cells such as

hepatocytes, adipocytes and muscle cells have relatively high levels of these
receptors, however, most cells possess some insulin receptors and thus, insulin may
affect physiological processes in these as well (Myers et al., 1993).
The insulin receptor is a heterotetrameric transmembrane glycoprotein
consisting of two extracellular hormone-binding a subunits and two intracellular
signaling p subunits containing tyrosine kinase activity (White et al., 1989). Binding
of insulin to the receptor activates the tyrosine kinase, leading to the
autophosphorylation of tyrosine residues on several regions of the intracellular P
subunit (Karlsson et al., 1979). This initiates a diverse metabolic and mitogenic signal
that reaches its final destination via an elaborate network of intracellular signaling
molecules (Figure 2). However, the precise intracellular routes of specific signals
responsible for defined aspects of insulin action are not fully understood.
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Figure 2.

Insulin Signal Transduction Pathway.

Autophosphorylation of the receptor leads to the immediate tyrosine
phosphorylation and activation of two families of intracellular proteins known as
insulin receptor substrate (IRS) and She. Three isoforms of the IRS protein have been
identified and designated IRS-1, IRS-2 and a less characterized IRS-3 (p60). IRS-1, a
135kda protein contains several potential tyrosine phosphorylation sites, at least eight
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of which are phosphorylated immediately in response to insulin (Myers et al.,1993}.
Some of these sites reside in a presumed consensus sequence (YXXM) that binds to
the src homology 2 (SH2) domain (a phosphotyrosine binding domain) of various
signaling proteins such as the 85-kda regulatory domain of phosphatidylinositol 3
kinase (Pl 3-K), SH-PTP-2, Grb 2 and Nck (Sun et al., 1992). IRS-2 and IRS-3 have
been shown to behave in a similar manner in relaying the phosphorylation signal,
however, differences in structural features and the levels found in cells suggest the
possibility of important differences between IRS-1, IRS-2 and IRS-3 proteins (Lavan
et al., 1997).
Both IRS-1 and IRS-2 have been shown to act as a docking protein that forms
a signaling complex with PI 3-K, and thus regulates the activity of PI 3-K. Although
the precise role of PI 3-K in insulin action remains unknown, activation of PI 3-K has
been implicated in the regulation of a variety of insulin mediated metabolic and
mitogenic cellular processes (Kappler et al., 1994). These include GLUT-4 mediated
glucose uptake, regulation of glycogen synthesis, transport of amino acids, DNA
synthesis, membrane ruffling, protein synthesis and transcription of genes, which are
important in glucose metabolism (e.g. PEPCK).
The heterodimeric PI 3-K is composed of an 85kda regulatory subunit (p85)
and a llOkda catalytic subunit (pll O). The p85 regulatory subunit contains multiple
domains that mediate interactions with regulatory proteins, such as two SH2 domains,
one src homology 3 (SH3) domain, two proline rich domains and a Ber homology
domain (Figure 3). The region between the tw� 2 domains of p85 is called the
inter SH2 (iSH2) region and it binds to the N-terminus of pl10 (Klippel et al., 1997).
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The insulin-induced activity of the PI 3-K is increased by binding of the two SH2
domaind to the phosphorylated YXXM motif on IRS-1. This dual association of the
SH2 domains of the PI 3-K to IRS-1 leads to a conformational change in the p85
subunit resulting in the activation of the catalytic subunit (Figure 4). Upon activation,

SH2

SH3

iSH2

SH2

Proline rich sequences
Figure 3. Structural Features of the PI 3-K p85 Regulatory Subunit.
the pllO catalytic subunit of PI 3-K is targeted to the membrane where it
phosphorylates phosphatidylinositol-4-monophosphate (PI-4-P) and phosphatidyl4,5-bisphosphate (PI-4,5-P2) on the D-3 position forming phosphatidyl-3,4bisphosphate

(PI-3,4-P2)

and

phosphatidyl-3,4,5-triphosphate

(PI-3,4,5-PJ

,

respectively (Whitman et al., 1998). An increase in their levels upon growth factor
and insulin stimulation suggests that these D-3 phosphorylated phosphatidylinositides
(PPI) are a novel class of secondary messengers (Mcilroy et al., 1997).
Inhibition studies of PI 3-K have shown its importance in regulating the
activation of several downstream kinases, such as Akt and S6 Kinase that have also
been implicated in insulin mediated metabolic and mitogenic responses. Akt is a 60
kDa serine/threonine kinase that is composed of an N-terminal pleckstrin homology
(PH) domain, followed by a catalytic domain and a short C-terminal tail. It is
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Figure 4. PI 3-K Activation by the IRS Protein.
activated by a variety of growth factors, such as platelet-derived growth factor
(PDGF), epidermal growth factor (EGF) and insulin. This activation by the growth
factors is prevented if the cells are preincubated with inhibitors of PI 3-K
(wortmannin and LY 294002) or by overexpression of a dominant negative mutant of
PI 3-K (Burgering et al., 1995), suggesting that Akt lies downstream of PI 3-K. The
mechanism by which A.kt is activated by PI 3-K is still unclear, however two models
have been proposed. Franke et al. (1995) and Klippel et al. (1997) have suggested that
the lipid products generated by PI 3-K partially activate Akt in vitro by binding to its
NH2 terminus PH domain. In direct contradiction to this proposed model, Kohn et al.
(1996) have shown that the association of Akt with the iSH2 region of the PI 3-K was
essential for the activation of A.kt, while the PH domain was not important for its
activation. Binding of the iSH2 region of the PI 3-K mediated the phosphorylation of
serine/threonine residues on the C-terminus leading to the membrane targeting and
the subsequent activation of A.kt by insulin. To address this controversy, Andjelkovic
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et al. (1996) have proposed that the lipid products of PI 3-K may be important in
binding to the PH domain of Akt and recruiting it to the membrane, where
serine/threonine kinases such as PB-K phosphorylate and activate the Akt kinase.
Another downstream target of PI 3-K is S6 Kinase (S6K). It is a
serine/threonine kinase that is responsible for phosphorylating the S6 protein of the
40S ribosome complex. Activation of S6K facilitates protein synthesis (Proud et al.,
1994). It has also been shown that S6 phosphorylation correlates with a selective
upregulation in the expression of a family of mRNAs containing a polypyrimidine
tract at their 5' untranslated region. These mRNAs encode ribosomal protein and
elongation factors (Terada et al., 1994). S6K has been shown to be directly
phosphorylated by PI 3-K (Weng et al., 1995), Akt (Burgering et al., 1995) and
FKBP12-rapamycin associated protein (FRAP) (Grammer et al., 1996). The
mechanism by which the upstream kinases regulate S6K activation is unclear.
However, a recent model suggests that the rapamycin sensitive protein FRAP is
necessary for the mitogen stimulated phosphorylation of S6K at the C-terminus which
"primes" the enzyme so it can be fully activated by the PI 3-K or Akt (Grammer et
al., 1996). The precise role of FRAP and its mode of activation is not clear and needs
further attention.
The proteins mentioned above IRS/PI 3-K/AKT/S6K/FRAP form one branch
of the insulin induced signaling cascade commonly referred to as the PI 3-K pathway.
On the other hand, autophosphorylation of the receptor can also lead to the activation
of the She/Ras/Raf proteins and subsequent activation of the mitogen activated
protein kinase (MAPK) cascade.
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Upon phosphorylation by the insulin receptor, IRS-1 and She compete for the
association with a 23 kda growth factor receptor binding protein (Grb2). Grb2
contains a single SH2 domain flanked by two SH3 domains. These SH3 domains
direct the association of Grb2 with a guanyl-nucleotide exchange factor for Ras,
termed son of sevenless (SOS), which facilitates the ·exchange of bound GDP for GTP
on the protein Ras (Seger et al., 1995). This exchange causes the activation of Ras,
which is further famesylated and targeted to the membrane. Once membrane bound,
Ras interacts directly with the N-terminus of Raf-1, a 7 5kda serine/threonine kinase
and recruits it to the membrane where it is activated by an unknown mechanism
(Wood et al., 1992). Subsequent to its activation, Raf-1 activates mitogen activated
protein kinase kinase (MAPK.K), commonly referred to as MEK. MEK is a
serine/threonine kinase and is highly specific in the activation of ERK-1 and ERK-2,
commonly known as MAP Kinase (MAPK).
The role of MAPK in insulin action is still controversial, however more recent
work has shown MAPK activation to be important in cellular differentiation and
mitogenesis. Activated MAPK has many nuclear and cytosolic targets. It has been
shown to phosphorylate transcription factors such as p62TcF, elk-1, c-jun, c-fos which
mediate insulin-induced gene expression. Activated MAPK has also been implicated
in the phosphorylation of upstream proteins in the pathway, such as SOS, causing the
desensitization of Ras activity (Waters et al., 1995) ensuring that the MAPK pathway
is not persistently activated.
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Insulin Mimetics
In recent years, great interest has surfaced for using insulin mimicking agents
or insulin mimetics as therapeutic agents for insulin-resistant or insulin-deficient
forms of diabetes mellitus. Selenate (Se) and vanadate (V) are two such compounds
that have been studied with regards to their insulin-mimetic properties.
Selenate
Selenium is a biologically essential trace element as it is an integral
component of several enzymes. Several studies have recently shown selenate to
effectively mimic the action of insulin. In isolated rat adipocytes, selenate has several
insulin-like effects, including stimulating tyrosine phosphorylation of numerous
endogenous cellular proteins, glucose transport, cAMP phospodiesterase activity, and
ribosomal S6 phosphorylation (Ezaki et al., 1990). Subsequent experiments in
streptozotocin (STZ) induced diabetic rats have confirmed these insulin-like effects of
selenate in normalizing blood glucose levels (Becker et al., 1996) as well as the
hepatic mRNA levels and activities of several enzymes that are important in
carbohydrate and fatty acid metabolism. Some of these include glucokinase, L
pyruvate kinase, phosphoenolpyruvate carboxykinase (PEPCK) and fatty acid
synthase, important enzymes of glycolysis, gluconeogensis and lipogenesis (Becker et
al., 1996), respectively.
While selenate has been shown to be a potent insulin-mimetic in isolated
adipocytes and in vivo, little work has been done on the mechanism by which selenate
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mediates its insulin-like effects. Studies, in isolated adipocytes and hepatocytes have
shown that several proteins of the insulin signal transduction pathway, such as the
insulin receptor, IRS-1 and MAPK, are phosphorylated in response to treatment with
selenate (Ezaki et al., 1990 and Stapleton et al., 1996). This suggests that selenate
mediates its action on gene expression via a tyrosine phosphate signal transduction
cascade in a manner similar to insulin.
Vanadate
Vanadate, in its various forms, has also been shown to be an effective insulin
mimetic both in vivo and in vitro. Pugazhati et al. (1991) have shown that in diabetic
rats, treatment with vanadate normalized the blood glucose levels by increasing
glucose uptake and incorporation into glycogen. Furthermore, the decreased levels of
key enzymes of carbohydrate and fatty acid metabolism such as glycogen synthase
and malic enzyme were also normalized in these animals. In vitro studies with
cultured rat adipocytes, hepatocytes and muscle cells have also reported several
insulin-like properties of vanadate. These include an increase in glucose incorporation
into lipid (Duckworth et al., 1988), increase in the levels of fructose-2, 6bisphosphate, 6-phosphofructo 2-kinase (Miralpeix et al., 1990) and glucokinase (Gil
et al., 1988), inhibition of gluconeogenesis (Gil et al., 1988) and lipolysis (Mooney et
al., 1989). Non-insulin like effects of vanadate have also been demonstrated in rat
hepatocytes where treatment with vanadate inactivated glycogen synthase and
activated glycogen phosphorylase (Bosch et al., 1987). These effects are opposite to
that observed with insulin.
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Several studies aimed at investigating the mechanism of vanadate action have
found vanadate to activate the insulin receptor (Pugazhenthi et al., 1991) and its
downstream proteins IRS-1 (Fantus et al., 1995) and MAPK (Wagle et al., 1998).
However, the mechanism by which vanadate regulates the expression of metabolic
genes is still obscure and needs further investigation.Use of Inhibitors to Elucidate Signaling Cascades
Chemical inhibitors have been instrumental in determining the role of certain
signaling proteins in defined aspects of insulin action. Inhibitors of the protein PI 3-K
showed that this protein was essential for insulin induced glucose uptake, amino acid
uptake, protein synthesis, DNA synthesis and S6K activation in 3T3 Ll adipocytes
(Cheatman et al., 1994). Wortmannin, a fungal metabolite, and a structurally distinct
chemical 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (also known as LY
294002) (Vlahos et al., 1994), are two well-characterized inhibitors of PI 3-K.
Wortmannin inactivates PI 3-K by binding and modifying the catalytic subunit (pl 10)
of the enzyme (Wyamann et al., 1996), whereas LY294002 behaves as a competitive
inhibitor for the ATP binding site of PI 3-K. Similarly, B581 (Cox et al., 1994) and 2(2 '-amino-3 '-methoxyphenyl)-oxanapthalen-4-one (PD 098059) (Vlahos et al., 1994),
inhibitors of proteins in the MAP Kinase pathway, have shown the importance of this
cascade in cellular proliferation, differentiation and development (Seger et al., 1995).
B581 mimics the CAAX binding site of farnesyltransferase and thus blocks the
membrane localization of Ras and subsequent activation of downstream proteins. PD
098059 on the other hand is a specific inhibitor of MEK. Both B581 and PD 098059
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are potent inhibitors of MAPK activation in a variety of cell types. An effective
inhibitor of S6K, rapamycin has also been characterized. Rapamycin in association
with FRAP causes the rapid dephosphorylation and thus inactivation of S6K.
These inhibitors have been used to elucidate the mechanism by which insulin
regulates key enzymes in a variety of metabolic processes. Some of these enzymes
include hexokinase, glycogen synthase, PEPCK and fatty acid synthase which are
important in glycolysis, glycogen synthesis, gluconeogenesis and fatty acid synthesis,
repectively. However, key enzymes of the pentose phosphate pathway have not been
characterized with regard to insulin action.
Glucose-6-Phosphate Dehydrogenase
Glucose-6-phosphate dehydrogenase (G6PDH) is a key regulatory enzyme of
the pentose phosphate pathway. It controls the flow of carbon through this pathway
catalyzing the net transfer of a hydride ion to NADP+ from glucose-6-phosphate to
produce NADPH and 6-phosphoglucono-8-lactone.
G6PDH is present in most tissues and multicellular organisms where it is
constitutively expressed, however in several tissues such as the liver, muscle, lung
and adipose tissues, G6PDH gene expression and enzyme activity are regulated by
diet, hormones and growth factors (Kletzein et al., 1995). In the liver, this enzyme
plays an important role in both carbohdyrate and lipid metabolism. During periods of
carbohydrate excess, G6PDH is the primary enzyme responsible for shuttling 50% of
the glucose-6-phosphate down the pentose phosphate pathway (Kletzein et al., 1995).
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The NADPH that is produced as a result is employed in reductive biosynthesis of
fatty acids and cholesterol and in the maintenance of reduced glutathione.-Therefore,
understanding the mechanism by which G6PDH is regulated is of major importance,
as it will provide us with a greater insight into the regulation of both carbohydrate and
fatty acid metabolism.
Our lab has recently demonstrated that insulin and its mimetics, selenate and
vanadate, regulate G6PDH gene expression and enzyme activity (Berg et al., 1995)
both in vivo and in primary rat hepatocytes. The mechanism by which they regulate
G6PDH gene expression, however, has not been characterized.
Objective of Study
The objective of this study is to elucidate the signal transduction pathway by
which insulin and its mimetics, selenate and vanadate, regulate G6PDH gene
expression. Of particular interest is the question whether the mimetics utilize similar
signaling proteins/pathway as insulin to regulate G6PDH gene expression. The
studies were carried out in primary rat hepatocytes which provided us with an
excellent insulin-responsive model that would mimic in vivo conditions.

CHAPTER II
METHODS
Materials
Waymouth's MB 752/1 media was purchased from Gibco BRL, together with
the TRizol® and the Lipofectin® reagent. The hyaluronadase, BSA and the trypsin
inhibitor were from Sigma. Collagenase D was purchased from Boehringer
Mannheim. The Nucleobound AX kit was obtained from the Nest group, whereas the
Luciferase Assay Kit and the Multiprime Labeling Kit were purchased from Promega
and Amersham, respectively. The porcine insulin used in the study was a gift from Eli
Lilly. Dr. Alan Saltiel of Parke-Davis Warmer Lambert generously provided PD
098059. B581 and LY 294002 were obtained from Biomol Research Laboratories.
Wortmannin was purchased from Sigma and rapamycin was from Calbiochem. All
chemicals used in the study were of the highest grade.
Hepatocyte Isolation and Maintenance
The hepatocytes were isolated from 8-10 week old male Sprague-Dawley rats
(Harlan Sprague-Dawley, Indianapolis, IN) which were food-deprived for 2 days
prior to sacrifice. Water was given ad libitum without restriction. The rats were
anesthetized with pentobarbital, and the liver was then perfused via the portal vein
with a digest solution containing 100 µg/ml colleganase D, 93 µg/ml hyaluronadase
15
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and 160 µg/ml trypsin inhibitor in a Mg2+ free Hepes balanced salt solution. The
partially digested liver was then forced through 4 layers of sterile gauze as previously
described by Stapleton et al. The resulting cell suspension was washed three times
with Waymouth's MB 752/1 media containing 0.5% bovine serum albumin (BSA).
The viability of the cells was checked with a hemocytometer using the brilliant blue
dye exclusion method. Cell preparations with an over 80% viability were then plated
on sterile 60mm collagen-coated culture plates and maintained at 37°C in

humified

environment of 5% CO2 and 95% air. After 4 hours the media was changed to BSA
free media and allowed to incubate overnight.
Plasmid DNA Preparation
The E. Coli bacteria containing the plasmid of interest was plated on Luria
Bertani (LB) agar plates containing 100 µg/ml of the antibiotic ampicillin. A single
colony was used to inoculate 1 liter of LB Medium containing 100 µg/ml ampicillin
and grown overnight at 37°C in a shaking incubator. The plasmid DNA was then
isolated using the alkaline lysis method as described by Sambrook et al. (1989) and
purified using the Nucleobond Ax silica based anion exchanger according to
manufacturer's instructions. Visualization of the purified DNA using gel
electrophoresis and the OD 260/280 absorption ratios confirmed the purity.
Transfection
The transfection of the hepatocytes was carried out using the Lipofectin®
reagent. Lipofectin reagent is a 1: 1 liposome formulation of the cationic lipids N-[-1-
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(2,3 -dioleyloxy)propyl]-n,n,n-trimethylammonium chloride (DOTMA) and dioleoyl
phophotidylethanolamine (DOPE) in membrane filtered water. The lipofectin reagent
(30 µg) was incubated for 10 minutes in 1 ml of BSA free waymouth's media. Then,
5 µg ofthe desired plasmid was added to the lipofectin media mixture and allowed to
sit for 30 minutes. This lipid: DNA complex was diluted to 4 ml and added to the
hepatocytes in culture. After 18 hrs, the media was changed and the cells were treated
with various conditions. The expression of the plasmid was checked 24 hrs after
dosing.
Cell Treatment
The cells were pretreated for 30 minutes with the concentrations of the various
inhibitors listed on Table 1 prior to treatment with 300 ng/ml porcine insulin, sodium
selenate (30µM) or sodium vanadate (30µM) for 22 hours. Two plates were used per
condition for each animal sacrificed.
Table 2
List ofInhibitors Used in the Study, Their Area ofAction and Concentration Used
Inhibitor

Area of Action

Concentration

B581

Inhibitor ofRas farnesylation

50µM

PD 098059

Inhibitor ofMEK

l0µM

LY29004

Inhibitor of PI 3 Kinase

50µM

Wortmaninn

Inhibitor ofPI 3 Kinase

l00 nM

Rapamycin

Inhibitor ofFRAP

l00 nM
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Cell Processing
The primary rat hepatocytes in culture were first processed by removing the
media and washing twice with cold phosphate-buffered-saline (PBS) solution. The
cells were then lysed by adding 400 µl of lx luciferase lysis buffer for 15 minutes and
then scraped off the plates. The samples were centrifuged for 30 seconds at 14,000 x g
to pellet the cell debris and the supernatant was transferred to a new tube and assayed
for luciferase activity as described below. The protein content was measured using the
Lowry method (Lowry et al., 1951).
Luciferase Assay
A 20 µl aliquot of the cell lysate was added to 100 µl of luciferase assay
reagent. The reaction that occurs is characterized in Figure 5.
Luciferase + Luciferin + ATP ------ ➔ Luciferase - Luciferyl-AMP +PPi
Luciferase - Luciferyl-AMP + 02

------

➔ Luciferase + oxyluciferin + AMP + CO2 + hv

Figure 5. Enzymatic Reaction Catalyzed by Luciferase.
The hv in the reaction represented in Figure 5 is then measured using the
scintillation counter. The average of two one-minute measurements was then
normalized to the amount of protein in the sample. The final values are in counts per
minute per µg of sample (CPM/µg).

19
RNA Isolation
Total RNA was isolated using TRizol® Reagent from Life Technologies
(Grand Island). TRizol® reagent is a monphasic solution of phenol and guanidine
isothiocynate. To ensure absence of RNAse contamination, the work area was
decontaminated with RNase ZAP (Invitrogen) and all glassware was baked. The
primary hepatocytes were lysed in the culture dish by adding 2 ml of TRizol® reagent
and passing the cell lysate several times through a pipette. The lysate was then
incubated at 15 to 30°C for 5 minutes to permit the complete disassociation of the
nucleoprotein complexes. This was followed by a chloroform extraction and
isopropanol precipitation. The precipitated RNA pellet was resuspended in
diethylpyrocarbonate (DEPC) treated water, and the RNA concentration was
quantified at optical density (OD) 260. The purity was assessed by the ratio of (OD)
260

I (OD) 2so (<1.5).
Total RNA (15 µg) was subjected to electrophoresis on a 1% agarose/ 2.2 M

formaldehyde gel. The separated RNA was then transferred to "GeneScreen"
(NEN/DUPONT) and hybridized with [32P] dCTP labeled G6PDH cDNA (Berg et al.,
1995). The cDNA was labeled by the random primer method using the mutiprime
labeling kit as described in the manufacturer's instructions. The membranes were then
washed and subjected to autoradiography at -70°C with Kodak XAR-5 film and
intensifying screens. The exposed films were quantified using densitrometric
scanning. The amount of G6PDH mRNA was normalized to the control 13-actin probe.

Statistical Analysis
The results are expressed as the means ± S.E.M. of N number of animals per

group with each determination being performed in duplicates. Statistical significance

was evaluated by thetudent's t test which is significant at p < 0.05.
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CHAPT ERIII
RESULTS
To elucidate the signaling proteins and /or pathways involved in the insulin
induced regulation of G6PDH gene, we used a series of well defined inhibitors (Table
1) to determine their effects on the signaling proteins of the insulin signal
transduction pathway as well the G6PDH gene expression. The expression of the
G6PDH gene was measured by (a) a G6PDH promoter driven luciferase gene
construct (Figure 6) tranfected into primary rat hepatocytes, and (b) the endogenous
G6PDH mRNA levels.

B..tmH/�61

pGL2-Baslc Vector
with G6PDH Promoter
Insert

Sm.ti 3

(6532bp)
-'YM/2978

Figure 6.

PGL-2 Basic Vector With a G6PDH Promoter Gene Insert.
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Insulin Induced Stimulation of G6PDH Gene Expression Is
Sensitive to LY 294002 and Wortmannin
LY 294002 and wortmannin are two structurally distinct inhibitors of PI 3-K.
PI 3-K has been shown to be important in a variety of insulin and growth factor
induced metabolic and mitogenic responses (Kapellar et al., 1994). As shown in
Figure 7 and 8 respectively, incubation of primary rat hepatocytes with insulin led to
a 2-3 fold increase in the G6PDH promoter driven luciferase activity as well as the
endogenous G6PDH mRNA levels. In the presence of either LY 294002 or
wortmannin, however, this insulin-induced stimulation is completely abolished.
Insulin Induced Stimulation of G6PDH Gene Is Sensitive to Rapamycin
S6K, a direct downstream target of PI 3-K (Weng et al.,1995), has been shown
to be essential for insulin and/or growth factor mediated regulation of some metabolic
genes important in glucose metabolism. With the aid of rapamycin, a potent inhibitor
of FRAP which is important in the activation of S6K, we analyzed the importance of
S6K activity on insulin induced G6PDH gene expression. Our results demonstrate
that the 2-3 fold increase in the insulin induced G6PDH promoter driven luciferase
activity (Figure 9), as well as the endogenous G6PDH mRNA levels (Figure 10), are
sensitive to rapamycin. This suggests a role for S6K in insulin induced G6PDH gene
expression.
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Figure 7.

Role of PI-3K on Insulin Stimulated G6PDH Promoter Driven Luciferase
Activity. Primary Hepatocytes were Pretreated with Either LY 294002
(50µM) or Wortmannin (l00nM) for 30 Minutes Prior to Stimulation
with Insulin (80nM) for 22 Hours. N=4
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Figure 8.

Role of PI 3-K on Insulin Stimulated G6PDH mRNA Levels. A.
Northern Blot Showing G6PDH Gene Expression. B. G6PDH mRNA
Levels. Primary Hepatocytes were Pretreated with LY 294002 (50µM)
for 30 Minutes Prior to Stimulation with Insulin (80nM) for 22 hours. N
=4
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Figure 9.

Role of S6K on Insulin Stimulated G6PDH Promoter Driven Luciferase
Activity. Primary Hepatocytes were Pretreated with Rapamycin l00nM)
for 30 Minutes Prior to Stimulation with Insulin (80nM) for 22 Hours.
N =5.

A.

26

• • •

NA

I

l+R

3()()-,------------------------------�
*

.,

200-1-------------

ai
>
.!!

<
�1Wt---------------l

**

E
:i::

Na

Legend.

l+R

Treatment

NA = No Addition, I = Insulin, R=Rapamycin
*= Significant Stimulation (P<0.05) **=Significant Inhibition (P< 0.05)

Figure 10.

Role of S6K on Insulin Stimulated G6PDH mRNA Levels. A. Northern
Blot showing G6PDH gene expression. B. G6PDH mRNA Levels.
Primary Hepatocytes were Pretreated with Rapamycin 100nM for 30
Minutes Prior to Stimulation with Insulin (80nM) for 22 Hour. N =5.

Insulin Induced Expression of the G6PDH Gene Is Not Sensitive to
Inhibitors of Ras Famesylation or MEK Activation
After establishing the importance of PI 3-K and S6K in the insulin induced
regulation of G6PDH gene expression, the role of proteins of the MAPK pathway in
the regulation of the G6PDH gene was determined. B581, an inhibitor of Ras
farnesylation and the MEK inhibitor PD 098059 have been proven to be effective
inhibitors of insulin induced MAPK activation in a variety of cell types. As seen in
Figures 11 and 12, neither inhibitor was effective in inhibiting the insulin induced
increase in the G6PDH promoter driven luciferase activity or the endogenous G6PDH
mRNA levels. In fact, pretreatment with the ras famesylation inhibitor, B581, before
stimulation with insulin, led to a significant increase (over insulin) in the G6PDH
promoter driven luciferase activity. This can be attributed to the fact that treatment of
primary rat hepatocytes with B581 by itself, led to a significant increase in the
G6PDH promoter driven luciferase activity over the basal (data not shown).
Together these data suggest that Ras/Raf/MAPK pathway is not involved in
the insulin mediated regulation of the G6PDH gene.
Selenate and Vanadate Do Not Utilize the Same Pathway as Insulin to
Regulate G6PDH Gene Expression
Previous studies by our laboratory have shown that the insulin mimetics
selenate and vanadate induce G6PDH enzyme activity and the mRNA levels (Berg et
al., 1995), both in vivo and in cells in culture. Both of these mimetics increase the
overall phosphorylation state of the cell, including phosphorylation of proteins
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Figure 11.

Role ofMAPK Activation on Insulin Stimulated G6PDH Promoter
Driven Luciferase Activity. Primary Hepatocytes were Pretreated with
Either B581 (50µM) or PD098059 (l0µM) for 30 Minutes Prior to
Stimulation with Insulin (80nM) for 22 hours. N=5
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Figure 12.

Role of MAPK Activation on Insulin Stimulated G6PDH mRNA
Levels. A. Northern Blot Showing G6PDH Gene Expression. B.
G6PDH mRNA Levels. Primary Hepatocytes were Pretreated with PD
098059 (l 0µM) or B581 (50µM) for 30 Minutes Prior to Stimulation
with Insulin (80nM) for 22 Hours. N =3.
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identified in the insulin signal cascade. To determine whether the mimetics utilize
similar signaling proteins/pathway in the regulation of the G6PDH gene, we carried
out inhibition studies similar to that previously described for insulin.
Selenate
Treatment of primary rat hepatocytes with selenate led to 2-3 fold increase in
G6PDH gene expression as demonstrated in Figures 13 and 14. This 2-3 fold increase
in G6PDH gene expression, similar to insulin, requires the activation of PI 3-K as
well as S6K (Figure 13), but not MAPK (Figure 14). More interestingly however,
using an inhibitor of Ras activation, it appears that selenate requires the membrane
targeting and subsequent activation of the protein Ras (Figure 14) to mediate its effect
on G6PDH gene expression. Together, these results demonstrate a unique mechanism
by which selenate regulates G6PDH gene expression by utilizing the protein Ras in
addition to PI 3-K and S6K.
Vanadate
The mechanism by which vanadate regulates G6PDH gene expression is also
unique and interesting. The 2-3 fold increase in G6PDH gene expression in response
to vanadate is PI 3-K dependent (LY 294002 sensitive) but S6K independent
(rapamycin insensitive) (Figure 15). Vanadate, in a mechanism similar to that of
insulin, however does not require the activation of the proteins Ras and / or MEK for
regulating G6PDH gene expression, since both B581 and PD 098059 have no effect
on vanadate induced G6PDH gene expression (Figure 16).
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Figure 13.

Role of PI 3-K and S6K on Selenate Stimulated G6PDH mRNA
Levels. A. Northern Blot showing G6PDH Gene Expression. B.
G6PDH mRNA Levels. Primary Hepatocytes were Pretreated with
L Y204002 (50µM) or Rapamycin (1 00nM) for 30 Minutes Prior to
Stimulation with Selenate (30µM) for 22 Hours. N =3.
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Figure 14.

Role of the MAPK Pathway on G6PDH rnRNA Levels. A. Northern
Blot Showing G6PDH Gene Expression. B. G6PDH rnRNA Levels.
Primary Hepatocytes were Pretreated with PD 098059 ( l0µM) or
B581 (50µM) for 30 minutes Prior to Stimulation with Selenate
(30µM) for 22 Hours. N=3.

33

250,------------------------------,

*
200+--------------=----------------+---------1

1150+------- --G)

..J
c(

z
It:

E
:::c
�100+----,-,--,,.
co
C)

NA

Legend.

Treatment

V+LY

V+R

NA= No Addition, V = Vanadate, LY =LY 294002, R = Rapamycin
*= Significant Stimulation (P<0.05) **=Significant Inhibition (P< 0.05)

Figure 15.

Role of PI 3-K and S6K on Vanadate Stimulated G6PDH mRNA
Levels. Primary Hepatocytes were Pretreated with Either LY 294002
(50µM) or Rapamycin (l00nM) for 30 Minutes Prior to Stimulation
with Vanadate (30 µM) for 22 Hours. N=4
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Figure 16.

Role of the MAPK pathway on vanadate Stimulated G6PDH m.RNA
Levels. Primary Hepatocytes were Pretreated with Either B58l
(50µM) or PD 098059 (l0µM) for 30 Minutes Prior to Stimulation
with Vanadate (30µM) for 22 Hours. N =4

CHAPTER IV
DISCUSSION
Insulin affects the expression of a variety of metabolic genes by an elaborate
network of signaling molecules. The precise molecular mechanism by which it exerts
its tissue specific effect is an area of intense interest and study. Metabolic genes such
as PEPCK (Gabbay et al., 1996) and FAS (Moustaid et al., 1994), important in
carbohydrate and fatty acid metabolism respectively, have been extensively
characterized in this respect and have revealed diverse regulatory mechanisms.
G6PDH, a key rate-limiting enzyme of the pentose phosphate pathway plays a pivotal
role in both carbohydrate and fatty acid metabolism. Apart from controlling the
carbon flow through the pentose phosphate pathway, it produces reducing equivalents
in the form of NADPH, which are utilized in synthesis of fatty acids and cholesterol.
Understanding the molecular mechanism by which insulin regulates G6PDH gene
expression is therefore important, as it provides us with an ideal model to study the
regulation of both carbohydrate and fatty acid metabolism by insulin. The
physiological roles of proteins of the insulin induced signaling cascade in glucose
metabolism have been extensively characterized using chemical inhibitors. The
inhibition of the insulin-induced PI 3-K activity by wortmannin and a structurally
distinct chemical LY 294002 have revealed the obligatory role of this enzyme in
insulin induced glucose uptake, amino acid uptake, DNA synthesis, protein synthesis,
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glycogen synthesis as well S6K activation (Sanchez-Margalet et al., 1994).
Furthermore, the PI 3-K inhibitors have also been shown to effectively block the
action of insulin on gene 33 and PEPCK gene expression in hepatoma cells (Yang et
al., 1995). Consistent with these studies, which demonstrate the obligatory role of PI
3-K in a variety of insulin mediated metabolic processes, our results show that PI 3-K
activity is essential for insulin to regulate G6PDH gene expression.
The signaling events that lie downstream of PI 3-K are still unclear. One
protein that has been demonstrated to lie downstream of PI 3-K is S6K. S6K is a
serine/threonine kinase responsible for insulin induced phosphorylation of the 40S
ribosomal protein S6 (Chung et al., 1994). We used the inhibitor rapamycin to
examine the physiological role of S6K in the propagation of the signal to the nucleus.
Rapamycin is a potent inhibitor of insulin stimulated S6K activity and has no affect
on the PI 3-K activity. In 3T3 Ll adipocytes, insulin stimulated glycogen synthase
activity, as well as glycogen synthesis, is sensitive to rapamycin (Sheperd et al.,
1995). The insulin stimulated hexokinase II mRNA levels in skeletal muscle cells,
was also shown to be inhibited by rapamycin (Osawa et al., 1996). More recently
however, several reports have also suggested that the metabolic affects of insulin are
mediated by rapamycin insensitive pathways that diverge from PI 3-K and do not
require S6K as the downstream effector. In 3T3 Ll adipocytes, insulin induced DNA
synthesis, regulation of glucose transport and activition of glycogen synthase kinase
have all been shown to be regulated in this rapamycin insentive manner (Lazar et al.,
1995 and Cohen et al., 1997). Furthermore, expression of insulin regulated metabolic
genes such as PEPCK (Sutherland et al., 1996), gene 33 and glyceraldyhde-3-
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phosphate dehydrogenase (O'Brien et al., 1991) are all rapamycin insensitive. In
contrast to these findings, our results demonstrate that insulin induced G6PDH gene
expression is sensitive to rapamycin.
Akt, a serine/ threonine kinase, is also a downstream target of PI 3-K. It has
been shown to mediate some of the rapamycin insensitive responses of insulin. The
association of Akt with PI 3-K is required for insulin stimulated activation of Akt
(Kohn et al., 1996), and this activation is sensitive to PI 3-K inhibitors without being
affected by rapamycin. Wagle et al. (1998) have shown that in primary rat
hepatocytes insulin activated PI 3-K associates with Akt, which is abolished by
inhibitors of PI 3-K. Since Akt can stimulate S6K activity (Burgering et al., 1995) it
provides us with an attractive model of dual control of S6K by PI 3-K in primary rat
hepatocytes, directly or indirectly via Akt.
Activation of the Ras

➔

Raf

➔

MEK

➔

MAP kinase pathway is another

major component of insulin signal transduction. Previous studies have suggested that
the Ras/MAPK pathway plays a pivotal role in insulin induced mitogenesis and c-fos
gene expression (Davis et al., 1993). This pathway however, may not be required for
many of the metabolic effects of insulin. To elucidate the importance of this pathway
in the regulation of G6PDH gene expression we used two well characterized
inhibitors, B581 and PD098059, that have been shown to block the activation of
MAPK in various cell types (Dudley et al., 1995) (Cox et al., 1994). B581, a recently
identified inhibitor prevents the post-translational famesylation and the subsequent
membrane localization and activation of Ras. Although B581 blocks insulin induced
activation of MAPK, it fails to suppress G6PDH gene expression in primary rat
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hepatocytes. In addition to B581, we used an inhibitor of a downstream kinase MEK,
PD098059, to further assess the role of MAPK activation in the insulin-mediated
regulation of the G6PDH gene. Our results show that the insulin stimulated MAPK
activity is partially but significantly inhibited in the presence PD098059 (Wagle et al.,
1998) and this inhibition does not affect the insulin mduced G6PDH gene expression
in primary rat hepatocytes. This partial inhibition of MAPK by PD098059 is not
affected by increasing concentrations of the MEK inhibitor, suggesting that a MEK
independent pathway in primary rat hepatocytes can activate MAPK. This MEK
independent pathway does not involve PI 3-K since PI 3-K inhibitors have no effect
on insulin stimulated MAPK activity (Wagle et al., 1998).
In light of the evidence, we conclude that insulin regulation of the G6PDH
gene does not require the activation of the Ras/MAPK pathway but is dependent on
PI 3-K and S6K activation.
In recent literature, selenate and vanadate have both been reported to exhibit
insulin-mimetic properties. Several studies, both in vivo and in isolated cells in
culture, have shown selenate and vanadate to have many insulin like effects, including
stimulating tyrosine phosphorylation of endogenous cellular proteins, glucose
transport and expression of various genes important in glucose metabolism. However,
very little work has been done concerning the mechanism by which these mimetics
mediate their action. Our study focused on the mechanism by which selenate and
vanadate regulated G6PDH gene expression in primary rat hepatocytes.
Previous

studies

have

demonstrated

that

selenate

induces

rapid

phosphorylation of intracellular proteins involved in the insulin signal transduction
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cascade. In NIH 3T3 HIR3.5 cells selenate induced the phosphorylation of the insulin
receptor �-subunit and IRS-1 (Pillay et al., 1992). Stapleton et al. (1996) have further
shown that in addition to the insulin receptor �-subunit and IRS-1, selenate also
stimulates the phosphorylation and activation of MAPK in primary rat hepatocytes
and 3T3 Ll adipocytes. More recently, Wagle (1998) demonstrated that selenate
stimulates PI 3-K activity by a mechanism unlike insulin in that it does not require
IRS-1 association for activation. This suggests that PI 3-K is activated by an IRS-1
independent mechanism. Our results suggest the possibility that Ras is responsible for
the selenate induced PI 3-K activity. Ras has been shown to regulate PI 3-K activity
both in vivo and in vitro by several investigators (Rodriguez-Viciana et al., 1994).
Although the relationship between selenate induced Ras activity and PI 3-K activity is
unclear in primary rat hepatocytes, it is interesting to observe that the inhibition of
Ras farnesylation with B581 abolishes the selenate induced G6PDH gene expression.
In comparison to insulin, further studies with inhibitors have revealed that activation
of PI 3-K as well as S6K is also necessary for selenate to stimulate G6PDH gene
expression, whereas activation ofMAPK is not. Together these results reveal a unique
mechanism to that of insulin, by which selenate regulates G6PDH gene expression
through the protein Ras in addition to PI 3-K and S6K.
The mechanism by which vanadate regulates G6PDH gene expression in
primary rat hepatocytes is also very unique and interesting. Vanadate, in a manner
similar to insulin and selenate, required the activation of PI 3-K for regulating
G6PDH gene expression. However, the activation of the protein S6K, which is
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essential for insulin and selenate to regulate G6PDH gene expression, is not required
by vanadate to mediate its action. This reveals a rapamycin insensitive mechanism by
which vanadate regulates G6PDH gene expression. It is possible that Akt, the protein
downstream of PI 3-K, may be responsible for mediating these rapamycin insensitive
affects since Akt activity has been shown to increase in response to treatment of rat
adipocytes with vanadate and peroxvanadate (Wijkander et al., 1997). However,
further studies need to be done to show the effects of vanadate on Akt activity in
primary rat hepatocytes.
Vanadate, in a manner similar to that of insulin and selenate, did stimulate
MAPK activity, however, this activation occurred in a Ras and MEK independent
fashion, since inhibition with B581 and PD 098059 did not affect the vanadate
induced MAPK activity (Wagle, 1998). Therefore, the importance of MAPK
activation on vanadate induced G6PDH gene expression is not known. This MEK
independent activation of MAPK, was also seen previously by Band et al. using
bisperoxovanadium 1,10-phenentrolin (bpV(phen)).

It has been suggested that

vanadate, a potent phosphatase inhibitor, inhibits a specific tyrosine/ threonine
phosphatase involved in the negative regulation of MAPK, such that activation of
MAPK (by a MEK independent pathway and/ or autophosphorylation) (Misra-Press
et al., 1994) is unopposed. One such group of phosphatases that mediate the
dephosphorylation of MAPK are the MAPK phosphatases (MKP). Several isoforms
of the MKP have been identified (MKP-1, MKP-2, MKP-3, MKP-4) and they differ
in levels found in cells and tissue distribution (Misra-Press et al., 1994). Furthermore,
the importance of Ras activation as measured by inhibiting Ras with B58 l on
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vanadate induced G6PDH gene expresssion is not clear (p= 0.08) and also needs
further investigation.
From the results presented here, we conclude that the mechanism by which
insulin regulates G6PDH gene expression requires the proteins IRS-1/PI 3-K/S6K and
not the proteins of the Ras/Raf/MAPK pathway. Furthermore, it is interesting to
observe that the mechanism(s) by which the insulin mimetics, selenate and vanadate,
regulate G6PDH gene expression are different from that of insulin.

Appendix A
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